About TriSalus Life Sciences
TriSalus Life Sciences is a publicly listed company based in Westminster (United States) founded in 2009. Developer of drug delivery devices to treat cancers. TriSalus Life Sciences has raised $83.37 million across 12 funding rounds from investors including MCG Capital, Nantahala Capital Management and Broadfin Capital. The company has 110 employees. TriSalus Life Sciences offers products and services including Drug Delivery Technology, nelitolimod, and TriNav Infusion System. Its focus areas include Life Sciences, Drug Delivery, Intravenous and Oncology. Its legal entity is TriSalus Life Sciences, Inc. Its competitors include Insulet, Lyra Therapeutics and Credence MedSystems; 3 of its 3 listed competitors have raised funding.
Company details
TriSalus Life Sciences is involved in developing drug delivery devices to treat cancers. They have developed a technology platform, Pressure-Enabled Drug Delivery (PEDD), which is designed to improve the distribution and penetration of therapy in solid tumors.
- Headquarters Westminster, United States
- Employees 110
- Stage Public
- SectorsHealthcare
- Email••••••••
- Website trisaluslifesci.com
- Social LinkedIn X
- Legal Name Trisalus Life Sciences, Inc.
- Annual Revenue$45.15 M (USD)53.41as on Dec 31, 2025
- Net Profit-$39.23 M (USD)-30.56as on Dec 31, 2025
- EBITDA-$26.32 M (USD)25.14as on Dec 31, 2025
- Total Equity Funding$83.37M (USD)
in 12 rounds
- Latest Funding Round$22M (USD), Post-IPO
Apr 2025
- InvestorsMCG Capital
& 8 more
- Employee Count110
Products & Services of TriSalus Life Sciences
TriSalus Life Sciences offers a comprehensive portfolio of products and services, including Drug Delivery Technology, nelitolimod, and TriNav Infusion System.
Platform for enhancing drug delivery to tumors.
Candidate therapy for liver and pancreatic tumor treatment.
System for pressure-enabled drug administration in tumors.
Funding Insights of TriSalus Life Sciences
TriSalus Life Sciences has successfully raised a total of $83.37M across 12 strategic funding rounds. The most recent funding activity was a Post-IPO round of $22 million completed in April 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $83.37M
- Total Rounds 12
- Last Round Post-IPO — $22M
- First Round $3.69M
(Apr 2011)
- Investors Count 9
Latest 10 of 12 funding rounds of TriSalus Life Sciences with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr 2025 | $22M | Post-IPO | – | Nantahala Capital Management | |
| Dec 2024 | $999,984 | Post-IPO | – | – | – |
| Oct 2022 | $15.32M | Post-IPO | – | – | – |
| Sep 2021 | $23.5M | Post-IPO | – | – | – |
| Mar 2021 | $81.39M | Post-IPO | – | – | – |
| Mar 2017 | $12.86M | Series D | – | ORI Capital | – |
| Nov 2015 | $15.05M | Series C | – | Tullis Health Investors | |
| Jun 2015 | $11.05M | Series A | – | – | – |
| Nov 2013 | $18.2M | Series B | – | MCG Capital | |
| Sep 2013 | $16.42M | Series B | – | Partisan Management Group, High Country Ventures | – |
9 investors in total: 9 institutional.
Investors in TriSalus Life Sciences
TriSalus Life Sciences has secured backing from 9 investors, including institutional and venture fund investors. Prominent investors backing the company include MCG Capital, Nantahala Capital Management and Broadfin Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Investment opportunities in healthcare are managed by Broadfin Capital. | 2005 | broadfin.com | Melville, United States | |
A venture capital firm focused on early-stage biotech investments. | 2015 | ori-capital.com | Hong Kong, Hong Kong | |
Healthcare investments are made by Tullis Health Investors. | tullisfunds.com | Palm Beach Gardens, United States | ||
| kmgcap.com | ||||
| partisanmgmt.com | ||||
Early-stage centric life sciences and tech focused VC firm investing primarily in the US | highcountryventure.com | Boulder, United States | ||
Growth equity is provided to early-stage SMEs by MCG Capital. | 1990 | mcgcapital.com | Arlington, United States | |
Fundamentally-driven firm investing in micro-cap stocks with long and short strategies. | 2004 | nantahalapartners.com | New Canaan, United States | |
| mcgpartners.com |
Investor details for TriSalus Life Sciences
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of TriSalus Life Sciences
54 people are tracked at TriSalus Life Sciences (19 in leadership, 21 in board & advisors, 14 in team); the tracked headcount is 110.
| Name | Role | Group |
|---|---|---|
Caitlin Schaefer | Vp, Chief Accounting Officer | Leadership |
Katia Byers | VP Clinical Marketing | Leadership |
Matthew Goodman | Director Of Financial Reporting | Leadership |
Michael Gonzaga | Director Of Technical Operations | Leadership |
Mary T. Szela | CEO & President | Leadership |
David Patience | Chief Financial Officer | Leadership |
Sean Murphy | CFO | Leadership |
Brenda Zimmerman-Vertin | Sr. Director, Operations | Leadership |
Thomas Campbell-Salley | Director Of Fp&a | Leadership |
Kristine Zewe | Vice President Human Resources | Leadership |
Russell Causey | VP & Corporate Controller | Leadership |
Steve Kilburn | Vice President of Quality | Leadership |
Zaragoza Briseno Jr. | Vice President Operations | Leadership |
Jodi Devlin | President, Therapeutics | Leadership |
Robert Knight | Medical Director | Leadership |
Dan Giordano | VP Of Finance Operations | Leadership |
Julie Walker, RN, BSN, PHN | Director of Clinical Marketing | Leadership |
Susan Arshonsky | Marketing Director | Leadership |
Bryan F. Cox | Chief of Research | Leadership |
Anil Singhal | Director | Board & advisors |
34 more people are available in the full profile.
Complete people profiles for TriSalus Life Sciences
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of TriSalus Life Sciences
TriSalus Life Sciences is a publicly listed company on the NASDAQ with ticker symbol TLSI in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date19 Mar 2021
- Listed onNASDAQ: TLSI
- Listed entityTriSalus Life Sciences, Inc.
- Exchange sectorHealth technology
- ISINUS89680M1018
- Share price$4.00 (-3.38% on the day) · 2026-10-13
- Market capitalisation$246.3M
- EPS (diluted, trailing year)$-1.29
- Volume (last session)120,145
Financials of TriSalus Life Sciences
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | $45.1M | -$39.2M | -$26.3M |
| 2024 | $29.4M | -$30.1M | -$35.2M |
| 2023 | $18.5M | -$59.4M | -$52.6M |
| 2022 | $12.4M | -$47.2M | -$35.0M |
| 2021 | $4.8M | -$3.0M |
Detailed financial statements for TriSalus Life Sciences
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of TriSalus Life Sciences
4 dated milestones of TriSalus Life Sciences across 16 years, from founding to its latest funding, stage changes and deals.
- Founded TriSalus Life Sciences is founded.
- Funding First funding round of $3.7M.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO, of $22.0M.
Competitors of TriSalus Life Sciences
TriSalus Life Sciences has 3 listed competitors in our database, 3 of them funded. They include Insulet, Lyra Therapeutics and Credence MedSystems.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| insulet.com | 2000 | Boston, United States | $120.4M | 2,600 | Wearable insulin infusion systems are developed for diabetes patients. | |
| lyratherapeutics.com | 2005 | Watertown, United States | $127.61M | 75 | Small molecule therapeutics for ENT diseases are developed. | |
| credencemed.com | 2011 | Menlo Park, United States | $112.61M | Developer of smart devices for drug delivery |
Detailed competitors of TriSalus Life Sciences
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of TriSalus Life Sciences
The website of TriSalus Life Sciences (trisaluslifesci.com) receives about 5.1K visits a month.
- Monthly visits5.1K
▲ 11.9% vs previous month
Top companies in Biopharma Outsourcing & Drug Delivery
3 companies that operate in the same segment as TriSalus Life Sciences (Biopharma Outsourcing & Drug Delivery) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Suite solutions are provided for payers and healthcare providers. | 1998 | Princeton, New Jersey, United States | USD 220 M | USD 374.1 M | 5,666 | |
Wearable insulin infusion systems are developed for diabetes patients. | 2000 | Boston, Massachusetts, United States | USD 120.4 M | USD 2.71 B | 3,900 | |
Developer of small-molecule drugs | 1991 | Los Angeles, California, United States | USD 50 M | USD 348.97 M | 407 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Trisalus Life Sciences
Complete news archive for TriSalus Life Sciences
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about TriSalus Life Sciences
TriSalus Life Sciences was founded in 2009 and raised its 1st funding round 2 years after it was founded.
TriSalus Life Sciences is headquartered in Westminster, United States.
TriSalus Life Sciences is a funded company, having raised a total of $83.37M across 12 funding rounds to date. The company's 1st funding round was a Series B of $16.42M, raised on Apr 2011.
TriSalus Life Sciences has 110 employees.
Annual revenue of TriSalus Life Sciences is $45.15M as on Dec 31, 2025.
TriSalus Life Sciences is involved in developing drug delivery devices to treat cancers. They have developed a technology platform, Pressure-Enabled Drug Delivery (PEDD), which is designed to improve the distribution and penetration of therapy in solid tumors.
TriSalus Life Sciences's top competitors include Insulet, Lyra Therapeutics and Credence MedSystems.
TriSalus Life Sciences offers Drug Delivery Technology, nelitolimod, and TriNav Infusion System.
Yes, TriSalus Life Sciences is publicly traded on NASDAQ under the ticker symbol TLSI.
TriSalus Life Sciences has 9 investors. Key investors include MCG Capital, Nantahala Capital Management, Broadfin Capital, ORI Capital, and Tullis Health Investors.
TriSalus Life Sciences operates through Trisalus Life Sciences, Inc..